Drug Profile
WY 50295
Alternative Names: WY 50295-tromethamineLatest Information Update: 05 Oct 2011
Price :
$50
*
At a glance
- Originator Wyeth
- Class Antiallergics; Antiasthmatics; Antirheumatics
- Mechanism of Action 5-lipoxygenase inhibitors; Leukotriene D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 01 Jul 1998 No-Development-Reported for Asthma in USA (Unknown route)
- 01 Jul 1998 No-Development-Reported for Rheumatic disorders in USA (Unknown route)
- 14 Dec 1994 Investigation in Rheumatic disorders in USA (Unknown route)